Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,121 to 1,140 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Germline Mutation Analysis in Sporadic Breast Cancer Cases With Clinical Correlations. | Front Genet | 2022 | 35356428 | PubTator, text mining | PubMed |
| Lessons From Pediatric MDS: Approaches to Germline Predisposition to Hematologic Malignancies. | Front Oncol | 2022 | 35356204 | PubTator, text mining | PubMed |
| Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. | Breast Cancer Res Treat | 2022 | 35353237 | PubTator, text mining | PubMed |
| Fanconi Anemia Pathway in Colorectal Cancer: A Novel Opportunity for Diagnosis, Prognosis and Therapy. | J Pers Med | 2022 | 35330396 | PubTator, text mining | PubMed |
| PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. | J Clin Med | 2022 | 35330059 | PubTator, text mining | PubMed |
"You Always Have It in the Back of Your Mind"-Feelings, Coping, and Support Needs of Women with Pathogenic Variants in Moderate-Risk Genes for Hereditary Breast Cancer Attending Genetic Counseling in Germany: A Qualitative Interview Study. | Int J Environ Res Public Health | 2022 | 35329227 | PubTator, text mining | PubMed |
| Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy. | Int J Mol Sci | 2022 | 35328658 | PubTator, text mining | PubMed |
| Liquid Profiling for Cancer Patient Stratification in Precision Medicine-Current Status and Challenges for Successful Implementation in Standard Care. | Diagnostics (Basel) | 2022 | 35328301 | PubTator, text mining | PubMed |
| Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis. | Cancers (Basel) | 2022 | 35326723 | PubTator, text mining | PubMed |
| Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance? | Cancers (Basel) | 2022 | 35326684 | PubTator, text mining | PubMed |
| Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in BRCA1/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing. | Cancers (Basel) | 2022 | 35326583 | PubTator, text mining | PubMed |
| Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. | Cancers (Basel) | 2022 | 35326540 | PubTator, text mining | PubMed |
| Uptake of genetic counseling and testing in a clinic-based population of women with breast cancer. | Cancer Med | 2022 | 35322585 | PubTator, text mining | PubMed |
| Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. | J Gynecol Oncol | 2022 | 35320892 | PubTator, text mining | PubMed |
| PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies. | J Gynecol Oncol | 2022 | 35320891 | PubTator, text mining | PubMed |
| Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group. | Curr Oncol Rep | 2022 | 35320498 | PubTator, text mining | PubMed |
| Do current family history-based genetic testing guidelines contribute to breast cancer health inequities? | NPJ Breast Cancer | 2022 | 35319016 | PubTator, text mining | PubMed |
| DNA repair defects in cancer and therapeutic opportunities. | Genes Dev | 2022 | 35318271 | PubTator, text mining | PubMed |
| Assessment of a cancer genomic profile test for patients with metastatic breast cancer. | Sci Rep | 2022 | 35315838 | PubTator, text mining | PubMed |
| Candidate master microRNA regulator of arsenic-induced pancreatic beta cell impairment revealed by multi-omics analysis. | Arch Toxicol | 2022 | 35314868 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=57